Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMB NASDAQ:LIMN NASDAQ:ME NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMBINmune Bio$1.91-4.0%$2.34$1.71▼$11.64$50.77M1.031.48 million shs574,097 shsLIMNLiminatus Pharma$1.59-11.2%$4.45$1.58▼$33.66$41.36MN/A976,987 shs619,582 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsRLMDRelmada Therapeutics$1.51-5.9%$0.85$0.24▼$3.98$49.95M0.741.22 million shs264,556 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMBINmune Bio+1.02%+11.80%-21.34%-72.51%-63.05%LIMNLiminatus Pharma-3.24%-26.94%-55.25%+178,999,900.00%+178,999,900.00%ME23andMe0.00%0.00%0.00%0.00%-92.72%RLMDRelmada Therapeutics-4.19%+2.56%+147.64%+128.60%-47.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMBINmune Bio$1.91-4.0%$2.34$1.71▼$11.64$50.77M1.031.48 million shs574,097 shsLIMNLiminatus Pharma$1.59-11.2%$4.45$1.58▼$33.66$41.36MN/A976,987 shs619,582 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsRLMDRelmada Therapeutics$1.51-5.9%$0.85$0.24▼$3.98$49.95M0.741.22 million shs264,556 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMBINmune Bio+1.02%+11.80%-21.34%-72.51%-63.05%LIMNLiminatus Pharma-3.24%-26.94%-55.25%+178,999,900.00%+178,999,900.00%ME23andMe0.00%0.00%0.00%0.00%-92.72%RLMDRelmada Therapeutics-4.19%+2.56%+147.64%+128.60%-47.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMBINmune Bio 2.57Moderate Buy$18.40863.35% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/AME23andMe 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.00Hold$1.00-33.55% DownsideCurrent Analyst Ratings BreakdownLatest ME, INMB, RLMD, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMBINmune Bio$10K5,076.78N/AN/A$1.45 per share1.32LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ARLMDRelmada Therapeutics-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)Latest ME, INMB, RLMD, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMBINmune BioN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMBINmune BioN/A4.204.20LIMNLiminatus PharmaN/AN/AN/AME23andMeN/A1.050.91RLMDRelmada TherapeuticsN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMBINmune Bio12.72%LIMNLiminatus PharmaN/AME23andMe36.10%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipINMBINmune Bio35.70%LIMNLiminatus PharmaN/AME23andMe26.32%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMBINmune Bio1026.58 million17.09 millionOptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/AME23andMe77026.83 million19.77 millionNot OptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableME, INMB, RLMD, and LIMN HeadlinesRecent News About These CompaniesRelmada Therapeutics regains compliance with Nasdaq min bid price requirementSeptember 16 at 7:25 PM | msn.comRelmada Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 16 at 9:32 AM | quiverquant.comQRelmada Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 16 at 9:00 AM | globenewswire.comRelmada Therapeutics CEO remains ‘optimistic’ about company’s futureSeptember 10, 2025 | msn.comRelmada Therapeutics Provides Transformational Update and Strategic Outlook in Shareholder LetterSeptember 10, 2025 | quiverquant.comQRelmada Issues Mid-Year CEO Letter to ShareholdersSeptember 10, 2025 | globenewswire.comExclusive: Relmada CEO says his recent buy reflects ’significant undervaluation’September 4, 2025 | finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer StudySeptember 2, 2025 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comRelmada Therapeutics Reports Promising Phase 2 Study ResultsAugust 11, 2025 | theglobeandmail.comRelmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025July 31, 2025 | globenewswire.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Can AI Defense Contracts Push Palantir Shares Higher?By Chris Markoch | August 19, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025Amazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025ME, INMB, RLMD, and LIMN Company DescriptionsINmune Bio NASDAQ:INMB$1.91 -0.08 (-4.02%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.52%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Liminatus Pharma NASDAQ:LIMN$1.59 -0.20 (-11.17%) As of 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Relmada Therapeutics NASDAQ:RLMD$1.50 -0.10 (-5.94%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.02 (+1.33%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
